Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q3GV
|
|||
| Former ID |
DPR000103
|
|||
| Drug Name |
S32504
|
|||
| Synonyms |
CHEMBL484599; SCHEMBL3831115; BDBM86473; LS-192133; S32504 (+); (+/-)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2h-naphth[1,2-b]-1,4-oxazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Preclinical | [1] | |
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Terminated | [2] | ||
| Company |
Shionogi
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H22N2O2
|
|||
| Canonical SMILES |
CCCN1CCOC2C1CCC3=C2C=C(C=C3)C(=O)N
|
|||
| InChI |
1S/C16H22N2O2/c1-2-7-18-8-9-20-15-13-10-12(16(17)19)4-3-11(13)5-6-14(15)18/h3-4,10,14-15H,2,5-9H2,1H3,(H2,17,19)/t14-,15-/m1/s1
|
|||
| InChIKey |
XKTRZPQOQOCNJU-HUUCEWRRSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D2 receptor (D2R) | Target Info | Modulator | [1] |
| Dopamine D3 receptor (D3R) | Target Info | Modulator | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Rap1 signaling pathway | ||||
| cAMP signaling pathway | ||||
| Gap junction | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| Hypothetical Network for Drug Addiction | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity ... J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012906) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.